EGFR and non-small cell lung carcinoma: Using the cobas EGFR test, which is FDA-approved for detection of EGFR mutations in plasma collected in K2EDTA tubes from patients with NSCLC [25], this analysis evaluated the performance of the Roche cfDNA tube.